Cencora (COR) Posts Record Earnings, Is The Stock Still Undervalued?

Cencora (COR) just posted a sharp swing in fiscal fourth quarter and full year 2026 results, moving from a prior quarterly loss to profit while pairing those numbers with a higher dividend and fresh 2027 guidance.

The latest earnings beat and higher dividend arrive after a mixed stretch for Cencora’s stock. The share price has gained 5.14% over the past month but is still down 1.57% year to date. Meanwhile, the 3 year total shareholder return of 72.67% and 5 year total shareholder return of 178.68% highlight how longer term holders have fared very differently from those focused on the recent 1 year total shareholder return decline of 6.82%.

Scan how Cencora compares with other healthcare distributors by exploring our hand picked list of solid balance sheet and fundamentals (24 results) while this earnings momentum is still front of mind.

Cencora now appears to be a very solid healthcare distributor, supported by record earnings, a richer dividend and a fresh 2027 roadmap. The harder call is whether the current share price fairly reflects that strength.

Most Popular Narrative: 9.7% Undervalued

Cencora closed at $333.56, while the most followed narrative anchors fair value at about $369.31, using a 7.24% discount rate and tying that to concrete earnings and buyback assumptions rather than vague optimism.

The main thing that has to go right is that specialty drug demand, aging populations, and acquisitions like OneOncology and RCA continue to support sustainable revenue growth and long-term earnings resilience across U.S. and International Healthcare Solutions.

The current valuation implies the market is not fully pricing in Cencora’s double digit adjusted operating income growth, rising adjusted EPS guidance, and sizeable buybacks at around US$268 per share. This narrative views that combination as an undervaluation.

See why 29 investors see Cencora as 10% undervalued.

Result: Fair Value of $369.31 (UNDERVALUED)

Still, two pressure points could upend this Cencora narrative: weaker profitability from high volume therapies and further contract or customer mix shifts.

Find out about the key risks to this Cencora narrative.

Next Steps

Mixed signals on Cencora so far. If this earnings story has you on the fence, move quickly, review the underlying data, and weigh both the 3 key rewards and 2 important warning signs.

Looking for more Cencora sized investment ideas?

Before closing this tab, put today’s insight to work by lining up a few fresh leads that match your own risk, income, and value priorities.

• Target potential upside in quality businesses by scanning a curated pool of 39 high quality undervalued stocks that combine strong fundamentals with appealing price tags.
• Build a steadier income stream by focusing on cash generators with resilient payouts using our selection of 8 dividend fortresses.
• Dial down risk while staying fully invested by filtering for companies on the 29 resilient stocks with low risk scores that pair healthier balance sheets with more measured volatility.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com